NDANASALSPRAY, METERED
Approved
May 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
1
Data completeness
6/8 — Strong
DYMISTA (azelastine hydrochloride and fluticasone propionate) by Viatris (2) is propionate; therefore, the mechanisms of actions described below for the individual components apply to dymista. First approved in 2012.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYMISTA is a fixed-dose combination nasal spray containing azelastine hydrochloride (histamine H1-receptor antagonist) and fluticasone propionate (synthetic corticosteroid) approved in 2012 for allergic rhinitis. It combines two distinct pharmacologic classes to address both immediate histamine-mediated symptoms and underlying inflammatory pathways. The product targets patients with moderate-to-severe allergic rhinitis who require dual anti-inflammatory and antihistamine coverage.
$0.487MPart D
LOE ApproachingDeclining
2mo to LOEAs a niche combination product approaching LOE with minimal Part D penetration (1,752 claims in 2023), the brand team is likely small and focused on defending remaining market share before generic erosion accelerates.
Mechanism of Action
propionate; therefore, the mechanisms of actions described below for the individual components apply to DYMISTA. These drugs represent two different classes of medications (histamine H 1 -receptor antagonist and synthetic corticosteroid). Azelastine Hydrochloride Azelastine hydrochloride, a…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on DYMISTA at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.